Literature DB >> 7912253

Dengue virus-specific memory T cell responses in human volunteers receiving a live attenuated dengue virus type 2 candidate vaccine.

T Dharakul1, I Kurane, N Bhamarapravati, S Yoksan, D W Vaughn, C H Hoke, F A Ennis.   

Abstract

A live attenuated dengue virus type 2 candidate vaccine (16681-PDK53) was evaluated in a phase I trial in 10 nonimmune adult volunteers. The dengue virus-specific memory T cell responses were analyzed as part of this study. Dengue virus-specific T cell proliferative responses were observed in all subjects after stimulating their peripheral blood mononuclear cells with live viruses or noninfectious viral antigens. The highest proliferative response was against dengue virus type 2, although cross-reactivity with other flaviviruses was detected to a lesser degree in some subjects. Dengue virus type 2-specific CD4+ and CD8+ cytotoxic T lymphocytes were generated in all vaccinees. This study investigated whether the candidate vaccine was efficacious in inducing dengue virus-specific CD4+ and CD8+ T cell memory after a single immunization in nonimmune recipients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7912253     DOI: 10.1093/infdis/170.1.27

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  18 in total

1.  Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development.

Authors:  Claire Y-H Huang; Siritorn Butrapet; Kiyotaka R Tsuchiya; Natth Bhamarapravati; Duane J Gubler; Richard M Kinney
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

2.  Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5' noncoding region and nonstructural proteins 1 and 3.

Authors:  S Butrapet; C Y Huang; D J Pierro; N Bhamarapravati; D J Gubler; R M Kinney
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

3.  Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine.

Authors:  C Y Huang; S Butrapet; D J Pierro; G J Chang; A R Hunt; N Bhamarapravati; D J Gubler; R M Kinney
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

4.  Early T-cell responses to dengue virus epitopes in Vietnamese adults with secondary dengue virus infections.

Authors:  Cameron P Simmons; Tao Dong; Nguyen Vinh Chau; Nguyen Thi Phuong Dung; Tran Nguyen Bich Chau; Le Thi Thu Thao; Nguyen Thi Dung; Tran Tinh Hien; Sarah Rowland-Jones; Jeremy Farrar
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

5.  Chimeric dengue 2 PDK-53/West Nile NY99 viruses retain the phenotypic attenuation markers of the candidate PDK-53 vaccine virus and protect mice against lethal challenge with West Nile virus.

Authors:  Claire Y-H Huang; Shawn J Silengo; Melissa C Whiteman; Richard M Kinney
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

6.  Sculpting the immunological response to dengue fever by polytopic vaccination.

Authors:  Hao Zhou; Michael W Deem
Journal:  Vaccine       Date:  2005-12-28       Impact factor: 3.641

7.  Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in Cynomolgus macaques.

Authors:  Jorge E Osorio; Joseph N Brewoo; Shawn J Silengo; John Arguello; Ioana R Moldovan; Magdalena Tary-Lehmann; Tim D Powell; Jill A Livengood; Richard M Kinney; Claire Y-H Huang; Dan T Stinchcomb
Journal:  Am J Trop Med Hyg       Date:  2011-06       Impact factor: 2.345

8.  Novel formulations enhance the thermal stability of live-attenuated flavivirus vaccines.

Authors:  O'Neil Wiggan; Jill A Livengood; Shawn J Silengo; Richard M Kinney; Jorge E Osorio; Claire Y-H Huang; Dan T Stinchcomb
Journal:  Vaccine       Date:  2011-07-29       Impact factor: 3.641

9.  Prospects for a dengue vaccine: progress and pitfalls.

Authors:  Sarah L George
Journal:  Mo Med       Date:  2014 Jul-Aug

10.  Anamnestic immune response to dengue and decreased severity of yellow Fever.

Authors:  Ricardo O Izurieta; Maurizio Macaluso; Douglas M Watts; Robert B Tesh; Bolivar Guerra; Ligia M Cruz; Sagar Galwankar; Sten H Vermund
Journal:  J Glob Infect Dis       Date:  2009-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.